Shire PLC (LON:SHP)‘s stock had its “buy” rating reissued by research analysts at Berenberg Bank in a research note issued on Wednesday.
Other equities analysts have also recently issued research reports about the stock. Shore Capital reissued a “buy” rating on shares of Shire PLC in a research note on Thursday, January 5th. Jefferies Group LLC reissued a “buy” rating and issued a GBX 6,600 ($83.07) price target on shares of Shire PLC in a research note on Thursday, January 5th. Deutsche Bank AG reissued a “buy” rating on shares of Shire PLC in a research note on Tuesday, January 3rd. Liberum Capital reissued a “buy” rating and issued a GBX 5,500 ($69.23) price target on shares of Shire PLC in a research note on Thursday, December 22nd. Finally, Bryan, Garnier & Co reissued a “buy” rating and issued a GBX 6,800 ($85.59) price target on shares of Shire PLC in a research note on Monday, January 9th. One analyst has rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of GBX 6,115.60 ($76.97).
Shares of Shire PLC (LON:SHP) traded up 1.10% on Wednesday, hitting GBX 4497.50. 1,962,535 shares of the company’s stock were exchanged. The stock’s 50 day moving average is GBX 4,716.00 and its 200 day moving average is GBX 4,710.64. Shire PLC has a 12 month low of GBX 2,707.19 and a 12 month high of GBX 5,377.00. The firm’s market cap is GBX 40.60 billion.
The company also recently declared a dividend, which will be paid on Tuesday, April 25th. Shareholders of record on Thursday, March 9th will be given a dividend of GBX 20.64 ($0.26) per share. The ex-dividend date is Thursday, March 9th. This represents a yield of 0.43%. This is a boost from Shire PLC’s previous dividend of $3.51.
In other news, insider William Burns purchased 136 shares of the company’s stock in a transaction on Friday, March 31st. The stock was acquired at an average price of GBX 4,742 ($59.69) per share, with a total value of £6,449.12 ($8,117.21).
About Shire PLC
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.